Surgical excision remains the standard of care for primary cardiac tumors. However, advances in catheter-based electrosurgical techniques have enabled minimally invasive resection of selected intracardiac masses.

A 19-year-old male patient was identified with a neoplasm in the right ventricle after a medical evaluation. The possibility of performing a transfemoral excision of the tumor was taken into consideration, as the patient wanted to pursue a professional football career. Coagulation was used to remove the mass, and snare systems were used to entirely retrieve it. The procedure was technically successful without any complications.

This method validates the technical viability of whole mass removal via venous access and broadens the use of transcatheter structural treatment of intracardiac masses.

Transcatheter removal of a right ventricular fibromyxoma may be a safe alternative to open surgery in certain patients. A successful outcome requires careful planning, precise visualization, and coordinated multidisciplinary teamwork.

Background: Cancer registry programs depend on strong organisational, procedural, and regulatory foundations. International standards, such as the International Agency for Research on Cancer (IARC)'s Technical Publication No. 43 (TP43) and guidelines from the International Association of Cancer Registries, provide guidance for low- and middle-income countries (LMICs). Nevertheless, adoption remains inconsistent, and many LMICs face structural, legal, and financial barriers. Objective: This scoping review aimed to synthesise and categorise essential criteria and standards that underpin effective cancer registries, and to propose an integrated framework that combines international guidelines (e.g. IARC) with context-specific adaptations for application in resource-limited settings. In addition, the review mapped the implementation status of IARC standards across identified cancer registries, revealing varying levels of adoption and contextual adaptation in LMICs. Method: Using Arksey and O'Malley's framework and PRISMA-ScR guidelines, English and Persian literature in international and national databases up to September 2025 were systematically searched. Eligible documents included peer-reviewed articles, official reports, and guidelines. Extracted data were thematically analysed and mapped to the 10 domains of the IARC framework, with additional elements identified beyond these domains to capture implementation gaps and context-specific adaptations. Results: Fifty-four sources were reviewed. We identified a comprehensive set of criteria and standards aligned with the 10 domains of the IARC framework, encompassing advisory committees, registry type, population denominators, legal aspects, population size, physical location, finance, personnel, equipment, and data management. Additionally, several supplementary domains beyond the IARC framework-including access to cancer cases, reporting and dissemination, and policymaking-were identified, highlighting context-specific challenges and adaptations, particularly in LMICs. Conclusion: By integrating global criteria and standards within a structured and context-sensitive framework, this review provides practical guidance for strengthening cancer registries, particularly in LMICs. Implications for health information management practice: Health information managers can use these findings to develop resilient, sustainable cancer registry systems, improve data quality, and support evidence-based policymaking-particularly in LMICs, where registry infrastructures remain underdeveloped, and system strengthening is a priority.

This study aimed to identify short message service (SMS) reminder content perceived as most likely to prompt bowel cancer screening, examine differences across sociodemographic subgroups, and explore preferences for timing and frequency.

Australian residents (N = 1016) aged 50-74 years completed an online survey rating five SMS reminders presented in random order. Outcomes included perceived usefulness, likelihood of encouraging kit return, likelihood of irritation and clarity. Preferences for timing and frequency were also assessed. Bayesian multilevel modelling (cumulative probit) compared ratings across SMS types, with effect sizes expressed as standard deviation (s.d.) differences in perceived likelihood that each SMS would encourage kit return compared with a reminder-only message. Interactions with age, gender, socioeconomic status and screening history were explored.

Compared with a 'reminder-only' message, SMS content that encouraged storing the kit near the toilet (s.d. 0.44), conveyed general practitioner endorsement (s.d. 0.32) and gave instructions (s.d. 0.22) was more likely to prompt kit return. Responses varied slightly by age and area-level socioeconomic status. Most participants preferred two to three SMS reminders (mean 2.89, s.d. 6.73).

SMS reminders using behavioural prompts and clear, concise content may support improved screening participation. Tailored SMS messages that reflect public preferences may increase kit return rates, support national screening goals and reduce bowel cancer mortality.

The standard treatment for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC) is still debated owing to insufficient evidence from clinical trials. An increasing number of clinical studies focus on investigating the use of immunotherapy in the treatment of oesophageal cancer. This phase II trial (NEOCRTEC-2001) aimed to assess the safety and efficacy of sintilimab in combination with cisplatin and nab-paclitaxel induction immunochemotherapy followed by surgery for BR-ESCC.

The NEOCRTEC2001 trial was a single-centre, open-label, nonrandomized, phase II study. Patients diagnosed with BR-ESCC were enrolled in the study and initially received 2-4 courses of induction immunochemotherapy at first. The subsequent treatment, surgery or definitive chemoradiotherapy, was determined based on reassessment by MDT. The primary endpoint of the study was the R0 resection rate.

From September 2020 to June 2024, a total of 50 eligible patients diagnosed with BR-ESCC were enrolled. All eligible patients underwent induction immunochemotherapy as the initial treatment. After induction immunochemotherapy, 35 of 50 patients (70.0%) were considered resectable, and 29 patients (58.0%) underwent surgery. R0 resection was achieved in 28 patients (56.0%, 95% CI, 41.4-69.1%), and 9 patients (18.0%) achieved pathological complete response. The median follow-up time of all patients was 29.43 months. Patients in the R0 resection group demonstrated significantly superior overall survival (OS) and progression-free survival (PFS) compared to those in the non-R0 group (OS: not reached vs. 19.84 months; HR  .25; 95%CI  .08-.79, p = .001; PFS: not reached vs. 19.82 months; HR  .30; 95%CI  .10-.90, p = .006).

The regimen under investigation did not exhibit the anticipated statistical benefit in enhancing surgical conversion rates for BR-ESCC. Nevertheless, the treatment strategy of induction immunochemotherapy followed by surgery resulted in significant tumour downstaging and a significant pathological complete response rate. Patients who achieved R0 resection exhibited improved survival outcomes.

The study was registered at ClinicalTrials.gov (NCT04548440) KEY POINTS: To the best of our knowledge, this is the first trial to evaluate the sintilimab combined with chemotherapy as an induction treatment for patients with BR-ESCC. The R0 resection rate in this study was 56.0%, and the pCR rate was 18.0%. Patients who achieved R0 resection exhibited improved survival outcomes.

Pseudomonas aeruginosa (PAE) is among the most frequent causes of bloodstream infections (BSIs) in cancer patients. Resistant strains are associated with increased morbidity and mortality.

A retrospective study was conducted at a tertiary oncology hospital in Mexico City, including all episodes of PAE-BSI. The isolates were classified as susceptible, carbapenem-resistant (CR), multidrug-resistant (MDR), or difficult-to-treat resistant (DTR).

A total of 259 PAE-BSI episodes were analyzed: 202 (78.4%) susceptible, 19 (7.3%) CR, 13 (5.0%) MDR, and 25 (9.7%) DTR. Resistant strains were significantly associated with prior antibiotic use (84.2% vs. 52.5%), more extended hospital stays (18 vs. 9 days), septic shock (36.8% vs. 19.8%), and inappropriate empiric therapy (54.4% vs. 19.3%). Overall, 30-day mortality was 38.2%, rising to 47.4% in CR, 84.6% in MDR, and 76% in DTR cases; compared with 29.7% in susceptible isolates (p < 0.001). No mortality benefit was observed with combination therapy compared to monotherapy. Multivariate analysis indicated that age ≥ 60 years, advanced oncological status, secondary bacteremia, septic shock, invasive mechanical ventilation, inadequate source control, and carbapenem strains were independent predictors of 30-day mortality. Appropriate antimicrobial therapy was a protective factor.

Resistant PAE-BSI in cancer patients was associated with longer hospitalizations and a significantly increased mortality rate. Appropriate antimicrobial therapy can lead to a reduction in mortality.

This study aimed to evaluate the psychological and behavioral impacts of the coronavirus disease-2019 (COVID-19) pandemic on cancer diagnosis and staging, with particular focus on patient delays and changes in healthcare-seeking behavior before and after the onset of COVID-19.

Data pertaining to 8 cancer types, including breast cancer, hepatocellular carcinoma, oral cancer, prostate cancer, gastric cancer, esophageal cancer, colon cancer, and lung cancer, sourced from the cancer registry database of Taichung Veterans General Hospital, was analyzed. The focus was on the comparisons of data between the pre-pandemic period (2017-2019) and the pandemic year (2020).

Breast cancer (p < 0.001), hepatocellular carcinoma (p = 0.004), prostate cancer (p < 0.001), gastric cancer (p = 0.037), and esophageal cancer (p < 0.001) exhibited a decrease in the rate of early stage patients and an increase in the rate of advanced stage patients after the COVID-19 outbreak. Furthermore, the number of newly diagnosed patients per year decreased for hepatocellular carcinoma, oral cancer, prostate cancer, gastric cancer, esophageal cancer, colon cancer, and lung cancer.

The COVID-19 pandemic disrupted cancer care, resulting in delayed diagnoses, stage migration, and a decline in newly diagnosed cases. These findings highlight the need for resilient healthcare systems to ensure continuity of cancer screening and treatment during global health crises.

The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years towards combination therapy, enhancing survival outcomes when compared with androgen deprivation therapy (ADT) alone. However, many patients who are eligible for combination therapy are still receiving ADT monotherapy, and a significant proportion of those treated with doublet combinations still experience suboptimal outcomes. Furthermore, the value of adding docetaxel to an androgen receptor pathway inhibitor (ARPI)/ADT doublet in mHSPC has not been delineated, particularly in patients with low-volume disease, and chemotherapy toxicity and tolerability remain a major concern for patients. This review addresses the significant unmet need for additional or novel treatment strategies for mHSPC, utilizing prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in a combination regimen that uses a non-chemotherapeutic approach for the treatment of mHSPC. PSMA-targeted RLT has been shown to improve survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with ARPIs +/- taxanes and is now under evaluation for the treatment of mHSPC, given its demonstrated success in the mCRPC space. Thus, continued education on RLT and its use for patients with mHSPC is important to optimize patient care. This review provides a brief outline of the mHSPC treatment landscape, focusing on the challenges and unique considerations faced by healthcare professionals when treating these patients. We also evaluate the potential role of RLT in surmounting these challenges, discussing potential barriers and solutions to its integration as a treatment for mHSPC.

IntroductionAdolescents and young adults (AYAs) with cancer experience substantial psychosocial distress, yet participation in supportive oncology services remains low. Community-based and nonprofit programs outside hospital systems provide essential developmentally appropriate supportive care, particularly during transitions to surveillance and longer-term follow-up, yet determinants of uptake in these settings are understudied. We examined program leaders' perspectives on participation gaps and strategies to strengthen equitable engagement beyond the hospital.MethodsWe conducted a qualitative interview study using semi-structured interviews with leaders of community-based and nonprofit AYA psychosocial support programs in the United States and Canada (N = 21). A structured environmental scan and expert verification yielded a 132-program sampling frame; 33 organizations expressed interest. Interviews were analyzed using the Framework Method, organized deductively with the Social Ecological Model and the Theoretical Domains Framework and refined inductively. Transcripts were double-coded, and themes were developed through team consensus.ResultsLeaders described multilevel determinants of uptake, including fragmented referral pathways, limited organizational capacity and program visibility, stigma and safety concerns, and misalignment between program structures and early adulthood realities. Timing was a cross-cutting determinant: engagement was described as least feasible during intensive treatment and especially vulnerable at transitions such as treatment completion and early survivorship, when routines shift and clinical contact decreases. A central finding was wide variability in sociodemographic data collection. Many programs did not routinely collect participant sociodemographic information, limiting their ability to identify representation gaps and tailor outreach. Leaders prioritized strategies including ethical sociodemographic data collection, trust-based community partnerships, clinician-facing referral workflow supports, and shared infrastructure for repeated needs assessment and resource matching.ConclusionLow participation was shaped by implementation conditions, not individual disinterest. Improving equitable uptake may require investments in referral and re-referral workflows across care transitions, equity-monitoring infrastructure, and community-embedded approaches that build trust and improve discoverability beyond the hospital.

The combination of transarterial chemoembolization (TACE), lenvatinib, and PD-1 inhibitors has shown promising efficacy in treating advanced hepatocellular carcinoma (HCC). However, the impact of hepatitis B virus (HBV) infection on the outcomes of this therapy remains unclear. This study aims to assess the association between HBV infection status and clinical outcomes in patients with initially unresectable HCC undergoing triple therapy.

This retrospective single-center cohort study included 190 consecutive uHCC patients treated with triple therapy between February 2022 and February 2025. Patients were stratified into HBV-positive (n = 133) and HBV-negative (n = 57) groups based on HBsAg status. Propensity score matching (PSM, 1:1, caliper 0.02) was performed to balance baseline characteristics. The primary endpoint was surgical conversion. Secondary endpoints included tumor response (mRECIST), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs). Landmark analyses, subgroup analyses and multivariate Cox regression were used to evaluate clinical outcomes and independent prognostic factors.

Compared to HBV-negative patients, HBV-positive patients achieved significantly higher surgical conversion rates both before PSM (25.6% vs. 12.3%, P = 0.041) and after PSM (20% vs. 10%, P = 0.021). After PSM, 30 matched pairs were included. Median OS was not reached in the HBV-positive patients and was 20.0 months in the HBV-negative patients (95% CI, 17.1-22.9; P = 0.014). Median PFS was 28.4 months (95% CI, 25.6-31.2) versus 17.3 months (95% CI, 14.8-19.9; P = 0.030). Tumor response was superior in the HBV-positive group, with higher ORR (36.7% vs. 20%, P = 0.043) and DCR (83.3% vs. 60%, P = 0.045). HBV-positive patients exhibited significantly prolonged OS (P = 0.014) and PFS (P = 0.030). Landmark analysis showed that the PFS advantage in HBV-positive patients no longer statistically significant (P = 0.118). Tumor diameter and HBV infection status were independent predictor of OS and PFS. Grade 3-4 AEs were comparable between groups, and no treatment-related deaths occurred.

HBV-positive status was associated with higher conversion rates and more favorable survival outcomes in unresectable HCC treated with TACE, lenvatinib, and PD-1 inhibitors. Prospective validation is needed to confirm these findings and clarify their biological basis.

This study evaluated the value of lipoprotein(a) (LPA) in lung adenocarcinoma (LUAD) patients receiving first-line chemoimmunotherapy and developed a model to predict progression-free survival (PFS) and grade 3/4 adverse events (G3/4 AEs).

A prospective cohort study was conducted on driver gene negative metastatic LUAD patients with PD-L1 TPS <50%, who received first-line chemoimmunotherapy. The data were randomly sampled into training and internal validation sets following a 7:3 proportion. We constructed a prognostic model for progression-free survival (PFS) via LASSO and multivariate Cox regression analyses. We explored five methods-random forest, AdaBoost, elastic-net, LASSO, and support vector machine (SVM)-to develop a prediction model for G3/4 AEs.

A total of 227 patients completed the follow-up. The AUC was 0.78(0.62-0.94) for 365-day PFS in the training cohort and 0.95(0.84-1.00) in the internal validation cohort. The serum LPA level independently predicted disease progression in patients receiving first-line chemoimmunotherapy. AdaBoost outperformed other machine learning methods in terms of accuracy, precision, recall, and F1 scores on both the training and validation sets, leading to its selection for the final G3/4 AE prediction model.

High LPA expression in the serum was a risk factor for metastatic driver gene-negative lung adenocarcinoma patients receiving first-line chemoimmunotherapy. Our models had favorable value in predicting PFS and G3/4 AEs, which might assist in identifying patients less likely to benefit from initial chemoimmunotherapy.